5 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related ComorbidityBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutritionActive, not recruitingPhase 22026-09-09NCT06965413
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDChronic Disease, Disease Attributes, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bronchial disorder, bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, pneumonia, pulmonary emphysema, respiratory system disorder, respiratory tract infectious disorderActive, not recruitingPhase 22026-07-20NCT06981078
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque PsoriasisPlaque PsoriasisActive, not recruitingPhase 32026-06-02NCT06550076
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled AsthmaHypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorderActive, not recruitingPhase 42026-05-22NCT06572228
Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-AntihistaminesChronic Disease, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticariaRecruitingPhase 22026-04-15NCT07415551